SRPT · Sarepta Therapeutics, Inc.
$18.10
-0.32 (-1.74%)
At close · Aug 14
Market Cap
$1.91B
Shares
105.63M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Douglas S. Ingram | Chief Executive Officer | $7,840,666 |
| Louise Rodino-Klapac | President, Research and Development and Technical Operations | $4,456,270 |
| Ian M. Estepan | President, Chief Operating Officer | $4,444,392 |
| Cristin L. Rothfuss | Executive Vice President, | $4,233,623 |
| Ryan H. Wong | Executive Vice President, Chief Financial Officer | $3,211,867 |
| Dallan Murray | Former Executive Vice President, Chief Customer Officer | $2,742,790 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Ian M. Estepan | Executive Vice President, Chief Financial Officer | $2,752,522 |
| Louise Rodino-Klapac | Executive Vice President, Head of R&D, Chief Scientific Officer | $2,737,283 |
| Dallan Murray | Executive Vice President, Chief Customer Officer Former Officer | $2,666,323 |
| Ryan E. Brown | Former Executive Vice President, Chief General Counsel and Corporate Secretary | $2,611,129 |
| Bilal Arif | Executive Vice President, Chief Technical Operations Officer | $2,539,138 |
| Douglas S. Ingram | President and Chief Executive Officer | $1,978,086 |
| Ryan H. Wong | Executive Vice President, Chief Financial Officer | — |
| Cristin L. Rothfuss | Executive Vice President, | — |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Louise Rodino-Klapac | Executive Vice President, Head of R&D, Chief Scientific Officer | $3,718,991 |
| Ian M. Estepan | Executive Vice President, Chief Financial Officer | $3,705,626 |
| Ryan E. Brown | Former Executive Vice President, Chief General Counsel and Corporate Secretary | $3,578,331 |
| Bilal Arif | Executive Vice President, Chief Technical Operations Officer | $3,520,586 |
| Douglas S. Ingram | President and Chief Executive Officer | $1,661,338 |
| General Counsel | Former Officer | — |
| Dallan Murray | Executive Vice President, Chief Customer Officer Former Officer | — |
| Ryan H. Wong | Executive Vice President, Chief Financial Officer | — |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Douglas S. Ingram | President and Chief Executive Officer | $124,938,694 |
| Louise Rodino-Klapac | Executive Vice President, Head of R&D, Chief Scientific Officer | $3,941,777 |
| Ian M. Estepan | Executive Vice President, Chief Financial Officer | $3,823,989 |
| Ryan E. Brown | Former Executive Vice President, Chief General Counsel and Corporate Secretary | $3,729,818 |
| Bilal Arif | Executive Vice President, Chief Technical Operations Officer | — |
| Dallan Murray | Executive Vice President, Chief Customer Officer Former Officer | — |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Louise Rodino-Klapac | Executive Vice President, Head of R&D, Chief Scientific Officer | $8,515,533 |
| Ian M. Estepan | Executive Vice President, Chief Financial Officer | $5,127,595 |
| Ryan Brown | Senior Vice President | $5,104,290 |
| Chief General Counsel | — | $5,104,200 |
| William F. Ciambrone | Executive Vice President, Technical Operations ^^ | $5,046,221 |
| Douglas S. Ingram | President and Chief Executive Officer | $1,546,324 |
| Bilal Arif | Executive Vice President, Chief Technical Operations Officer | — |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Gilmore O’Neill | M.B., M.M.Sc. Executive Vice President, Chief Medical Officer ^^ | $7,576,022 |
| Louise Rodino-Klapac | Executive Vice President, Head of R&D, Chief Scientific Officer ^^ | $7,269,883 |
| David Tyronne Howton | Executive Vice President, General Counsel and Corporate Secretary | $5,703,078 |
| Ian M. Estepan | Executive Vice President, Chief Financial Officer ^^ | $5,177,795 |
| Sandesh Mahatme | Executive Vice President, Chief Financial Officer and Chief Business Officer ^^ | $3,364,021 |
| Douglas S. Ingram | President and Chief Executive Officer ^^ | $1,291,947 |
| Joseph Bratica | Vice President, | $911,887 |
| William F. Ciambrone | Executive Vice President, Technical Operations ^^ | $680,419 |
| Ryan Brown | Senior Vice President | — |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Sandesh Mahatme | Executive Vice President, Chief Financial Officer and Chief Business Officer ^^ | $5,161,209 |
| William F. Ciambrone | Executive Vice President, Technical Operations ^^ | $4,345,194 |
| David Tyronne Howton | Executive Vice President, General Counsel and Corporate Secretary | $4,196,622 |
| Gilmore O’Neill | M.B., M.M.Sc. Executive Vice President, Chief Medical Officer ^^ | $3,790,049 |
| Douglas Ingram | President and Chief Executive Officer ^^ | $1,387,072 |
| Douglas S. Ingram | President and Chief Executive Officer ^^ | $1,387,072 |
| Joseph Bratica | Vice President, | — |
| Ian M. Estepan | Executive Vice President, Chief Financial Officer ^^ | — |
| Louise Rodino-Klapac | Executive Vice President, Head of R&D, Chief Scientific Officer ^^ | — |
| General Counsel | ^^ Former Officer | — |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Gilmore O’Neill | M.B., M.M.Sc. Executive Vice President, Chief Medical Officer ^^ | $5,168,110 |
| Sandesh Mahatme | Executive Vice President, Chief Financial Officer and Chief Business Officer ^^ | $4,219,084 |
| David Tyronne Howton | Executive Vice President, General Counsel and Corporate Secretary | $3,129,375 |
| Douglas S. Ingram | President and Chief Executive Officer ^^ | $1,433,872 |
| Douglas Ingram | President and Chief Executive Officer ^^ | $1,433,872 |
| Corporate Controller | ^^ | — |
| William F. Ciambrone | Executive Vice President, Technical Operations ^^ | — |
| Ian M. Estepan | Executive Vice President, Chief Financial Officer ^^ | — |
| Louise Rodino-Klapac | Executive Vice President, Chief Scientific Officer ^^ | — |
Fiscal 2017
| Executive | Role | Total |
|---|---|---|
| Douglas Ingram | President and Chief Executive Officer ^^ | $56,866,241 |
| Sandesh Mahatme | Executive Vice President, Chief Financial Officer and Chief Business Officer ^^ | $2,200,133 |
| David Tyronne Howton | Executive Vice President, General Counsel and Corporate Secretary ^^ | $1,823,528 |
| Gilmore O’Neill | M.B., M.M.Sc. Executive Vice President, Chief Scientific Officer ^^ | — |
| William F. Ciambrone | Executive Vice President, Technical Operations | — |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Michael Severino, M.D. | Class I director | Appointed | 2026-07-27 |
| Michael Severino, M.D. | Chief Executive Officer | Appointed | 2026-07-27 |
| Deirdre Connelly | director (Class I) | Appointed | 2026-06-04 |
| Michael Chambers | director (Class I) | Appointed | 2026-06-04 |
| Kathryn J. Boor, Ph.D. | director (Class I) | Appointed | 2026-06-04 |
| Hans Wigzell, M.D., Ph.D. | director (Class I) | Appointed | 2026-06-04 |
| Douglas S. Ingram | director (Class I) | Appointed | 2026-06-04 |
| Bilal Arif | Executive Vice President, Chief Technical Operations Officer | Terminated | 2025-08-13 |
| Louise Rodino-Klapac | President, Research and Development and Technical Operations | Appointed | 2025-07-16 |
| Ryan Wong | Executive Vice President, Chief Financial Officer | Appointed | 2025-07-16 |
| Ian Estepan | President and Chief Operating Officer | Appointed | 2025-07-16 |
| Claude Nicaise, M.D. | Director | Appointed | 2025-06-06 |
| Stephen L. Mayo, Ph.D. | Director | Appointed | 2025-06-06 |
| M. Kathleen Behrens, Ph.D. | Director | Appointed | 2025-06-06 |
| Richard J. Barry | Director | Appointed | 2025-06-06 |
| Deirdre Connelly | director | Appointed | 2024-09-16 |
| Bilal Arif | Chief Technical Operations Officer | Appointed | 2022-11-02 |
| William F. Ciambrone | Executive Vice President, Technical Operations | Resigned | 2022-11-02 |
| Hans Wigzell, M.D., Ph.D. | director (Class I) | Appointed | 2022-06-03 |
| Michael Chambers | director (Class I) | Appointed | 2022-06-03 |
| Douglas S. Ingram | director (Class I) | Appointed | 2022-06-03 |
| Kathryn Boor, Ph.D. | director (Class I) | Appointed | 2022-06-03 |
Key facts
CIK
873303
CUSIP
803607100
13F (30d)
333 filings
300 filers
Visit website
Investor relations